

Salish Kootenai College Institutional Review Board
Standard Operating Procedures
Revised February 2019

Table of Contents

I.	Introduction	3
II.	Background	3
III.	Types of Human Research	4
IV.	IRB Authority and Institutional Assurance	5
V.	IRB Roles and Membership	5
VI.	Responsibilities of Principal Investigators	7
VII.	Application for IRB Review	8
VIII.	IRB Procedures	9
IX.	Determination of Type of IRB Review	10
X.	Procedures for Exemption from Review	10
XI.	Procedures for Expedited Review	11
XII.	Procedures for Full Board Review	15
XIII.	Data Safety Monitoring Plans	17
XIV.	Disposal of Data and Biospecimens	18
XV.	Outcomes of IRB Review	18
XVI.	Written Notification of IRB Determination	18
XVII.	Continuing Review of Approved Research	18
XVII.	Suspension or Termination of IRB Approval of Research	18
XVIII.	SKC Student Class Projects Requiring Review	19
XIX.	IRB Procedures for Research Noncompliance and Research Participant Complaints	20

1 **I. Introduction**

2 The purpose of the Institutional Review Board (IRB) Standard Operating Procedures (SOP) is to provide
3 direction to the IRB membership and staff in carrying out duties assigned to the IRB. The SOP follows
4 existing SKC Policy as well as the regulatory requirements found in the Common Rule (45 CFR 46). At
5 the time of the release of Version 2 of the SKC IRB SOP, SKC is not carrying out research on new
6 investigational drugs or biomedical devices. Therefore, these SOP does not include requirements of
7 the Food and Drug Administration (FDA) regulations found at 21 CFR 56.

8 Per SKC Policy 1000, the SKC IRB addresses the dual functions of protecting human research
9 participants and the intellectual property rights of the Confederated Salish & Kootenai Tribes (CSKT).
10 The SKC IRB SOP are designed to provide guidance in both functions.

11 The SKC IRB reviews all human participant research according to the standards set in the Belmont
12 Report and the Common Rule, whether or not the research is funded by a federal entity. The SKC IRB
13 follows the Common Rule regulations regarding categories of review, informed consent, and other
14 areas as described in these SOP. Research deemed to pertain to the intellectual property rights of the
15 CSKT is reviewed according to the SOP below.

16 These SOP are considered to be a living document that will be updated or reviewed annually or as
17 needed as changes in statues, regulation, guidance, practice, or policy occur.

18 **II. Background**

19 The Salish Kootenai College IRB Procedures were developed with an understanding of the ethical
20 principles that apply to the conduct of research on humans, federal regulations found in the Common
21 Rule, and an understanding of the need for protection of research participants and the cultural
22 intellectual property rights of the Confederated Salish & Kootenai Tribes. Therefore, the Salish
23 Kootenai College Institutional Review Board is guided by the U.S. Federal Policy for the Protection of
24 Human Subjects, historical perspectives of ethical treatment of research participants, the Belmont
25 Report, as well as an understanding of the sovereignty of the Confederated Salish Kootenai Tribes and
26 the definition of Cultural Intellectual Property Rights.

27 a. The Nuremberg Code

28 The modern history of human subject protections began with the ten principles developed by the
29 Nuremberg Military Tribunal following documentation of the numerous atrocities committed by Nazi
30 doctors during World War II. These principles were meant to be a means of judging research practices
31 and were titled the Nuremberg Code. The code addresses the necessity of requiring the voluntary
32 consent of human research participants and that any individual who “initiates, directs, or engages in
33 the experiment” must bear personal responsibility for ensuring the quality of consent. The Nuremberg
34 Code also is a statement of research participants’ legal rights.

35

36 b. The Belmont Report

37 In the 1970’s, questionable research including the United States Public Health Service Study of
38 Untreated Syphilis in the Negro Male at Tuskegee resulted in legislation calling for regulations to
39 protect human research participants. The National Commission for the Protection of Human Subjects
40 of Biomedical and Biobehavioral Research produced a final report is known as the *Belmont Report*:

41 *Ethical Principles and Guidelines for the Protection of Human Subjects of Research.* The Report
42 provides three basic ethical principles:

- 43 1. Respect for persons (applied by obtaining informed consent, consideration of privacy and
44 confidentiality, and additional protections for vulnerable populations);
- 45 2. Beneficence (applied by weighing risks and benefits); and
- 46 3. Justice (applied by the equitable selection of participants).

47
48 c. Cultural Intellectual Property Rights United Nations Declaration on the Rights of Indigenous
49 Peoples, Article 31.1, "*Indigenous peoples have the right to maintain, control, protect and develop*
50 *their cultural heritage, traditional knowledge and traditional cultural expressions, as well as the*
51 *manifestations of their sciences, technologies and cultures, including human and genetic resources,*
52 *seeds, medicines, knowledge of the properties of fauna and flora, oral traditions, literatures,*
53 *designs, sports and traditional games and visual and performing arts. They also have the right to*
54 *maintain, control, protect and develop their intellectual property over such cultural heritage,*
55 *traditional knowledge, and traditional cultural expressions.*"

56

57 **III. Types of Human Research and Institutional Review Board Considerations**

58 Per SKC Policy 1000, all research performed by SKC faculty members, staff members, or students, and
59 all research being conducted at SKC by outside researchers, must be reviewed by the Institutional
60 Review Board.

61 The following definitions pertain to research review.

62 **Research** means a systematic investigation, including research development, testing and evaluation,
63 designed to develop or contribute to generalizable knowledge.

64 **Systematic Investigation** means that a careful plan is followed to gather information. According to the
65 Office of Human Subjects Protection (OHRP), a systematic investigation occurs when "...observations
66 are obtained under clearly specified, and, where possible, controlled conditions that can be measured
67 and evaluated."

68 **Generalizable knowledge** is information which has the potential to be expanded from the isolated
69 circumstances in which it is acquired to any broader context.

70 **Human subject or Human Research Participant** means a living individual about whom an investigator
71 (whether professional or student) conducting research: (i) Obtains information or biospecimens
72 through intervention or interaction with the individual, and uses, studies, or analyzes the information
73 or biospecimens; or (ii) Obtains, uses, studies, analyzes, or generates identifiable private information.

74 **Private Information or Personal Identifying Information (PII)** means personal information that a
75 research participant may normally consider to be private, or which through a combination of data
76 might reasonably lead to knowing the identify of a person. Examples include the study subject's
77 name, family names, social security number, computer IP address, photo identification, or other
78 such information.

79

80 **Cultural Intellectual Property** refers to traditional cultural knowledge, cultural expressions, sacred
81 cultural material, historical traditions and understandings, and other property such as natural
82 resources that occur on the Flathead Indian Reservation.

83
84 **Minors or Children** refers to "persons who have not attained the legal age for consent to
85 treatments or procedures involved in the research, under the applicable law of the jurisdiction in
86 which the research will be conducted." Under Montana law, a "Minor" refers to an individual who
87 is less than 18 years of age. A minor is considered to be emancipated if the minor is between 16
88 and 18 years of age, is married, in the military, or is emancipated via a court order.
89 Investigators with questions concerning whether an activity constitutes research with human
90 participants should contact the Chair of the SKC Institutional Review Board at the contact number
91 on the IRB website.

92
93 **IV. IRB Authority and Institutional Assurance**

94 The Chair of the Salish Kootenai College Institutional Review Board is SKC's Institutional Official, signs
95 the college's Federal-Wide Assurance, and works with the IRB members to oversee the Institutional
96 Review Board review of human research and research involving intellectual property rights of the
97 CSKT.

98 The SKC IRB is authorized under SKC Policy 1000 to carry out review, approval, and monitoring of
99 human research for SKC. The Roles and authority of the IRB are further described below. The college
100 administration may determine that a study may not be conducted, however, no study may be
101 conducted by researchers if the IRB has not approved the study. Thus, the IRB acts independently
102 from college administration in approving or disapproving research, setting requirements for
103 monitoring or reporting, or terminating a study. Undue influence by college administrators or staff
104 that may curtail the independence of the IRB are to be reported to the IRB Chair, who will investigate
105 the report and document resulting actions, if any.

106 The IRB has the sole authority to approve, disapprove, suspend, or terminate research based on these
107 procedures. The IRB may suspend or terminate research involving human participants as it determines
108 necessary to protect the participants or the cultural intellectual property of the Confederated Salish
109 and Kootenai Tribes. The IRB has the authority to observe and/or monitor approved research to the
110 extent it considers necessary to protect human participants.

111
112 Multi-Site Investigations and Collaborative Research

113 SKC researchers may participate in studies where investigators and/or study populations are involved
114 at more than one study location. An investigator is engaged in a multi-site study when the activity
115 involves multiple entities and/or research sites and meets the definition of human research or
116 involves cultural intellectual property of the Confederated Salish & Kootenai Tribes.

117
118 **The Salish Kootenai College Institutional Review Board does not accept reviews from outside**
119 **institutional review boards.**

120
121 **V. IRB Roles and Membership**

122

123 Federal Regulations require that Institutional Review Boards file a written “Assurance” of protections
124 for human research participants with the Office of Human Research Protections (OHRP), Department
125 of Health and Human Services (DHHS). The FWA is maintained on file in the Office of the Institutional
126 Review Board. Regulations also require training for IRB members and researchers as part of the
127 conditions of the FWA. SKC utilizes the online training program sponsored by the Collaborative
128 Institutional Training Initiative (CITI) for training both researchers and IRB members.

129

130 Membership of the IRB

131 The Common Rule requires that the IRB be comprised of at least five members, with at least one non-
132 scientist and at least one non-affiliated (or community) member. IRB members will represent a
133 diversity relative to gender, cultural background, and a sensitivity to community attitudes so as to
134 promote respect for the IRB’s counsel in safeguarding the rights and welfare of human research
135 participants. SKC seeks to maintain IRB membership that represents a balance of individuals with
136 expertise in research areas commonly pursued at the College as well as members who are CSKT tribal
137 members and able to represent tribal perspectives. One or more alternate IRB members may be
138 named on the IRB’s official membership roster; alternate IRB members should be able to represent
139 similar interests as the member he/she may replace.

140

141 Individuals are appointed to the IRB by the SKC President. IRB membership may continue until the
142 individual resigns the membership or is unable to fulfill membership responsibilities. Upon
143 appointment, IRB members complete the IRB member component of CITI training, sign a form
144 acknowledging responsibility for understanding the requirements of IRB membership and agreement
145 to maintain confidentiality of IRB reviews and materials, and agrees to participate in IRB meetings and
146 reviews. IRB members are not compensated for their service on the IRB. IRB members who participate
147 in trainings that are off the Flathead Indian Reservation may be provided with travel funding.

148

149 The IRB Chair will maintain a record of IRB membership including name, gender, earned degree(s),
150 specific scientific qualifications, area(s) of expertise, and cultural affiliation if a CSKT tribal
151 member/descendant.

152

153 The IRB Chair is appointed by the SKC President. The Chair is responsible for conducting IRB meetings,
154 ensuring IRB maintains operation within applicable regulatory requirements, and maintains IRB
155 records as required.

156 Consultants

157

158 The IRB chair may invite individuals with competence in special areas to assist in the review of
159 issues that require expertise beyond or in addition to expertise available by the
160 IRB members. Consultants may not vote with the IRB or approve a protocol. Consultants complete
161 an agreement that there is no conflict of interest related to the study and the subject of the study
162 will remain confidential.

163

164 Conflict of Interest

165 No IRB member may participate in the IRB’s initial or continuing review of any project in which the
166 member has a conflicting interest, except to provide information requested by the IRB. IRB members,

167 including the Chair, who have conflict interests are required to disclose those interests and recuse
168 themselves from deliberations, quorum counts, and votes on the relevant protocol.

169 Plan for Training IRB Members

170 IRB members will be required to update their CITI training every three years and provide
171 documentation of training to the IRB Chair. Additional annual trainings will occur at the first
172 meeting of each academic year to update the members on any changes in college or tribal
173 regulations, federal regulations, or other updates.
174 Additionally, all SKC IRB members receive copies of these SOP and other reference materials.
175 Additional trainings may be provided through regional or tribal human subject protection trainings.
176

177 Attendance at IRB meetings

178 Convened IRB meetings will list names of members present, names of members absent, alternates
179 attending in lieu of specified absent members, names of consultants present, names of guests present
180 (if any).
181

182 Quorum Requirements and Voting at Convened IRB Meetings

183
184 A convened IRB meeting will have a simple majority of members present in order to conduct official
185 IRB reviews. Members may be present in person or via audio (telephone) or audiovisual
186 teleconference. Members present via audio or audiovisual means will be noted as such in meeting
187 minutes.
188

189 **VI. Responsibilities of Principal Investigators**

190 As the individual responsible for the implementation of approved research, the principal investigator
191 bears direct responsibility for ensuring the protection of every research participant. This responsibility
192 starts with research design, which must minimize risks to participants while maximizing research
193 benefits. In addition, the Principal Investigator must ensure that all members of the research team
194 comply with the findings, determinations, and requirements of the IRB.

195 In the event that the research is being conducted outside the United States or on tribal lands, the
196 Principal Investigator will have primary responsibility for seeking and receiving approvals from local
197 IRBs or other review bodies as may be required by the cognizant foreign or tribal government.

198 Principal Investigators are responsible for ensuring that:

- 199 1. Training in protection of human research participants is completed by all researchers who will have
200 access to participant disaggregated data or be involved in data collection or analysis. SKC utilizes the
201 online training program sponsored by the Collaborative Institutional Training Initiative (CITI) for
202 training both researchers and IRB members.
- 203 2. Any research involving human participants or cultural intellectual property has been approved by
204 the SKC IRB.
- 205 3. The IRB is notified of all changes in the research protocol. No changes in approved research may be
206 initiated without prior IRB approval, except where necessary to eliminate immediate hazards to
207 participants.
- 208 4. Continuing review and approval has been accomplished within the time frame stipulated by the IRB.

- 209 5. Any stipulated reporting or monitoring requirements are met.
- 210 6. Final documentation and closure of the research protocol is accomplished within the stipulated time
- 211 frame. No research may be continued beyond the IRB-designated approval period.
- 212 7. The IRB is notified in writing if there are adverse impacts to research participants, including:
- 213 • Data breach or breach of confidentiality
- 214 • New information that indicates a change to the risks or potential benefits of the research
- 215 • Any harm experienced by a participant which is both unexpected and
- 216 • Change or violation of an approved protocol
- 217 • Termination, suspension, or restriction of a study by a sponsor or principal investigator
- 218 • The results of the research are returned to the community which was the subject of the study,
- 219 as included in the approved protocol.

220 The SKC IRB may consider certain participant categories to be more vulnerable to coercion or undue

221 influence, including children, prisoners, individuals with impaired decision-making capacity,

222 economically or educationally disadvantaged persons, or tribal elders. Additional safeguards should be

223 in place to ensure that the rights and welfare of these participants are protected. This includes

224 obtaining informed assent from all minors and informed consent from parents or legally responsible

225 adults.

226 **VII. Application for IRB Review**

227 Submission of IRB Materials for Review

229

230 The Salish Kootenai College Institutional Review Board accepts only electronic materials. All

231 documents should be sent to the IRB email, irb@skc.edu. Electronic materials are stored in a secured

232 IRB file share on the SKC server.

233

234 The Primary Investigator is responsible for making timely application to the IRB for review of

235 protocols.

236

237 IRB applications must include all pertinent materials: completed and signed IRB protocol, informed

238 consent and assent (for minors) documents, recruitment materials, copies of surveys or interview

239 materials, and other materials as listed. The IRB protocol must be signed and dated. If the researcher

240 is a student, the student's research chair or responsible faculty member must also sign the protocol.

241 The application must be complete prior to IRB review. Researchers submit incomplete applications,

242 e.g. missing informed consent forms or other materials, will receive an email from the SKC IRB

243 requesting the additional materials.

244

245 The SKC IRB requires a letter of permission from the site in which the research is to occur. The letter

246 of site permission may be obtained from the pertinent educational or tribal entity. A letter from one

247 or both of the Culture Committees may be required if the research involves cultural intellectual

248 property of the Confederated Salish & Kootenai Tribes. Guidance concerning the appropriate entity

249 from which to obtain a letter of site permission may be provided by the SKC IRB.

250

251 Access to current IRB forms and additional information about applying for review by the SKC IRB shall
252 be maintained on a website accessible to both internal and external stakeholders.

253 Investigator's Assurance

254 It is the responsibility of each PI to formally "assure" the IRB that the researcher(s) will comply with
255 regulations governing the protection of human participants. This assurance is supplied through the
256 PI's signature on the research protocol.

257 Additionally, aligned with principles of indigenous research, researchers are asked to assure that
258 results and/or findings of the research will be shared with participants, sponsors, and/or the
259 community of interest.

260 Seeking Informed Consent

261 The Principal Investigator is responsible for ensuring that informed consent procedures are followed
262 for all research participants. No informed consent may include any exculpatory language through
263 which the subject or the legally authorized representative is made to waive or appear to waive any of
264 the participants' legal rights, or releases or appears to release the investigator, sponsor, or its agents
265 from liability for negligence.

266 Informed consent forms must include all basic elements as required by CFR 46.116.6(b), unless
267 consent is waived by the IRB. Researchers should use the SKC Informed Consent form. The SKC IRB
268 will accept Informed Consent forms from other institutions if the form contains the required elements
269 as specified in CFR 46.116.6(b).

270 The IRB may waive the requirement for informed consent under the following circumstances:

271 (1) If the participants have provided broad consent for the storage, maintenance, and secondary
272 research use of identifiable private information.

273 (2) The research or demonstration project is to be conducted by or subject to the approval of state
274 or local government officials and meets the requirements of CRF46.116.(3)i.

275 (3) The research involves no more than minimal risk to the participants AND could not practicably
276 be carried out without the requested waiver or alteration, AND the waiver or alteration will not
277 adversely affect the rights and welfare of the participants AND wherever appropriate, the participants
278 or legally authorized representative will be provided with additional pertinent information after
279 participation.

280 (4) The IRB may also waive written consent if the research involves no more than minimal risk,
281 informed consent will be sought via telephone (e.g. prior to a telephone interview), and the waiver
282 will not adversely affect the rights and welfare of the participants.

283 (5) If the only record linking the subject and the research would be the informed consent form AND
284 the principal risk would be potential harm resulting from a breach of confidentiality; in that case the
285 subject or legally authorized representative will be asked whether the subject wants documentation
286 linking the participant with the research and the participant's wishes will govern.

287 If informed consent is waived, the IRB may require the investigator to provide participants with a
288 written statement about the research.

289

290 **VIII. IRB Procedures**

291 Regulations at 45 CFR 46.111 (“The Common Rule”) delineate specific criteria for approval of research.
292 The IRB will use the Standard Operating Procedures contained in this document to ensure that all
293 requirements are satisfied prior to approving proposed research.

294 IRB Protocol Tracking System

295 The IRB Director shall ensure the maintenance of a reliable, computerized protocol tracking
296 system.

297

298 Retention of IRB Records

299 Electronic records of all IRB materials will be retained in a password protected file for three years after
300 completion of the research project. Access to the IRB’s electronic records is limited to the IRB Chair,
301 IRB members, and officials of federal and state regulatory agencies including the Office for Human
302 Research Protections (OHRP). Other access to IRB records may be afforded to others with legitimate
303 need as determined by the IRB Chair and the SKC President.

304 Materials to be retained include:

- 305 • IRB Protocol and all other required materials as described in xx below.
- 306 • All electronic and/or written communication between the PI and the IRB
- 307 • Documentation of type of review, rationale for exempted and expedited reviews
- 308 • Documentation of convened meetings including meeting minutes and attendees
- 309 • Documentation of data monitoring activities conducted
- 310 • Documentation of project closeout
- 311 • Documentation of reports of unanticipated problems
- 312 • Reports of research misconduct and resulting actions following the procedure for research
313 misconduct below.
- 314 • Training records of IRB members

315

316 **IX. Determination of Type of IRB Review**

317 Research activities that involve human participants or cultural intellectual property will be reviewed
318 by the IRB Chair or Administrator, who will determine the category of review based on CFR 46.104 and
319 IRB policies.

320 The SKC IRB may consider certain participant categories to be more vulnerable to coercion or undue
321 influence, including children, prisoners, individuals with impaired decision-making capacity,
322 economically or educationally disadvantaged persons, or tribal elders. The IRB may request specific
323 additional safeguards to protect the rights and welfare of these participants.

324 **X. Procedures for Exemption from Review**

325 The following categories of human participants research are exempt from review:

326 (1) Research conducted in established or commonly accepted educational settings that specifically
327 involves normal educational practices that are not likely to adversely impact students' opportunity to
328 learn required educational content, or the assessment of educators who provide instruction.

329 (2) Research that only includes interactions involving educational tests (cognitive, diagnostic,
330 aptitude, achievement), survey procedures, interview procedures, or observation of public behavior if
331 at least one of the following criteria is met:

332 (1) The information obtained is recorded by the investigator in such a manner that the identity of
333 the human participants cannot readily be ascertained either directly or through identifiers linked to
334 the participants;

335 (2) Any disclosure of the human participants' outside the research would not reasonably place the
336 participants at risk of criminal or civil liability or be damaging to the participants' financial standing,
337 employability, educational advancement, or reputation, or

338 (3) The information obtained is recorded by the investigator in such a manner that the identity of
339 the human participant can be ascertained and linked to the participant, AND an IRB conducts a limited
340 IRB review to determine that there are adequate provisions to protect the privacy of participants and
341 to maintain the confidentiality of data.

342 Limited Review

343 If an IRB protocol meets the criteria for exemption from review, the IRB may conduct a limited IRB
344 review to determine that identifiable private information or identifiable biospecimens are maintained
345 with adequate provisions to protect the privacy of participants and to maintain the confidentiality of
346 data. Even if a protocol meets the criteria for exemption from review, the IRB may require
347 considerations or modifications to a protocol to maintain client confidentiality.

348 **XI. Procedures for Expedited Review**

349 The IRB may utilize an expedited procedure for the initial or continuing review of research that meets
350 eligibility criteria as set forth below and that falls within the Common Rule list of research eligible for
351 expedited IRB review.

352 Evaluating if Proposed Activities are No More than Minimal Risk

353 Most research falling within one or more of the categories below will, ordinarily, present no more
354 than minimal risk to participants and will be eligible for review through the expedited review
355 procedure. However, the IRB reviewer is required to evaluate all proposed research and consider
356 whether the proposed research is more than minimal risk.

357 In evaluating if the proposed research presents no more than minimal risk, an IRB reviewer should
358 consider the nature of the study procedures, the implications of study findings for the subject (e.g.,
359 the results of genetic testing of blood samples), other study characteristics, and steps taken to
360 minimize risk. The IRB reviewer should also consider the characteristics of the subject population,
361 including but not limited to age, health conditions, social or economic circumstances and experience
362 in relation to the anticipated harms and discomforts.

363 The expedited review procedure may not be used, for example, when identification of the participants
364 and/or their responses would reasonably place them at risk of criminal or civil liability or be damaging
365 to the participants' financial standing, employability, insurability, reputation, educational

366 advancement, or be stigmatizing, unless reasonable and appropriate protections will be implemented
367 so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal. In
368 evaluating the risks, the IRB reviewer should consider only those risks that may result from the
369 research (as distinguished from the risks of therapies participants would receive even if not
370 participating in the research).

371 If a protocol qualifies for expedited review, two assigned reviewers will complete their reviews in
372 accordance with IRB SOPs and discuss the review to reach consensus. Either reviewer may request
373 that the protocol be presented to the convened IRB for review. The names of the reviewers and the
374 category of expedited procedure will be documented in the IRB records.

375 Eligibility requirements for expedited review:

- 376 (1) The research presents no more than minimal risk to participants.
377 (2) The identification of the participants or their responses will not reasonably place them at risk of
378 criminal or civil liability or be damaging to their financial standing, employability, reputation, or be
379 stigmatizing, unless reasonable and appropriate protections will be implemented so that risks related
380 to invasion of privacy and breach of confidentiality are no greater than minimal.
381 (3) Research either a) does not involve the cultural intellectual property rights of the CSKT OR a
382 letter of consent from tribal council or a cognizant tribal entity is included with the protocol.

383 Categories of Expedited Review

384 (1) Categories one (1) through fourteen (14) apply to initial IRB review of research that has been
385 determined to be no more than minimal risk.

386 (2) Category fifteen (15) applies to continuing review of research previously approved by the
387 convened IRB that does not otherwise qualify for expedited review.

388 Note: Category 8(b) is never eligible for expedited review.

- 389 1. Research involving the use of drugs and medical devices only when condition (a) or (b) is met.
390 a. Research involving use of “over-the-counter” drugs, when used within their approved indications
391 and dosages, and exempt from the IND requirements of 21 CFR 312.
392 2. The collection of blood specimens for research purposes using techniques consistent with
393 routine clinical practice to minimize pain and risk of infection and within the following limits: (a)
394 from adults whose health will not be adversely affected by the blood draws who weigh at least 50
395 kg, the amounts collected should not exceed 550 ml in an 8-week period; or (b) from children² and
396 other adults whose health will not be adversely affected by the blood draws, the amounts collected
397 should not exceed the lesser of 150 ml or 3 ml per kg in an 8-week period. Examples: Finger stick,
398 heel stick, ear stick, venipuncture, collection of blood from an indwelling peripheral venous
399 catheter (not including a PICC line) placed for research purposes, or collection of blood from an
400 indwelling catheter already in place for clinical purposes.
401 3. Prospective collection of biological specimens, excluding blood, for research purposes by
402 noninvasive means and not requiring sedation for research purposes.
403 4. Prospective collection of biological specimens, excluding blood, for research purposes by
404 minimally invasive means and not requiring sedation for research purposes. Examples: (a) tissues
405 from non-facial, non-genital skin punch biopsy with allowable local anesthesia and limited to 2mm
406 in diameter and not requiring sutures; (b) Specimens collected by swab (nasal, oral, urethral,
407 vaginal, rectal); (c) teeth if routine patient care indicates a need for extraction.

408 5. Collection of additional information or biological specimens, excluding blood, for research
409 purposes during procedures already being performed for clinical purposes, provided the additional
410 collection does not introduce more than a minimal increase in risk, pain or discomfort over that
411 imposed by the underlying procedure. When extension of general anesthesia is required, it must
412 meet the criteria for minimal risk. Examples: (a) collection of additional bodily fluids and tissues
413 (e.g., peritoneal fluid, bone marrow or cerebrospinal fluid); (b) tissue collected from pap smears; (c)
414 collection of additional clinical information (e.g., vital signs, electroencephalography or
415 echocardiography).

416 6. Collection of information for research purposes through noninvasive procedures and
417 interventions routinely employed in clinical practice and not requiring general anesthesia or
418 sedation.

419 Examples: (a) physical sensors that are applied either to the surface of the body or used at a
420 distance; (b) testing sensory acuity; (c) magnetic resonance imaging without use of contrast agent
421 and using magnet and sequence parameters within accepted clinical use guidelines; (d)
422 electrocardiography, electroencephalography, thermography, detection of naturally occurring
423 radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow, and
424 transthoracic echocardiography; (e) measures of cognitive functioning;

425 7. Collection of information for research purposes through activities performed by persons in daily
426 life in individuals and groups whose health will not be adversely affected by the activities.

427 Examples: (a) moderate exercise, muscular strength testing, body composition assessment, and
428 flexibility testing; (b) measures of symptoms, mobility, range of motion, quality of life and activities
429 of daily living in patient and non-patient populations by clinical or other trained personnel (e.g.,
430 nurses, physicians, social workers, physical and occupational therapists); (c) manipulations of diet
431 and lifestyle; (d) measuring height, weight, circumference; (e) assessment of reading levels.

432 8. Activities at statistical and data coordinating centers or biospecimen repositories that are not
433 responsible for the primary oversight of the primary data collection activities and are not involved
434 in the primary collection of information or specimens, which may be ongoing at other sites.

435 9. Collection of information from voice, video, digital, or image recordings made for research
436 purposes that are not exempt under §__.104(d).

437 10. Research that only includes interaction involving (1) educational tests (cognitive, diagnostic,
438 aptitude, achievement); (2) survey procedures, interview procedures, or observation of public
439 behavior (including visual and auditory recording) not eligible for exemption under §__.104(d)(2)
440 either because there are risks to participants other than informational risks, or because the
441 informational risks are not addressed as specified under §__104(d)(2)(i) through (iii); (3) other data
442 collection procedures (e.g., written or computer-assisted interactions or assessments) where the
443 subject provides self-reports for the purposes of the research and/or may choose what data to
444 provide; (4) non-invasive physical or behavioral tasks or manipulation of the subject's environment;
445 and (5) observations of individual group behavior where the subject is a voluntary participant in the
446 behavior and is aware that data are being collected.

447 11. Benign behavioral interventions that are not eligible for exemption under §__.104(d)(3)
448 because they (a) involve children as participants; (b) involve individuals with impaired decision-
449 making capacity; (c) are conducted without the prospective agreement of the subject, including
450 interventions involving deception; (d) are not brief in duration, or; (e) are not limited to verbal or
451 written responses by the subject, data entry by the subject, or observation of the subject.

452 12. Creation and maintenance of subject databases to which participants have provided
453 prospective informed consent or informed consent has been waived by an IRB and does not qualify
454 for exemption under §__.104(d)(7). Examples: (a) collection of identifiable information for the
455 purpose of establishing subject pools; (b) disease-specific patient registries; (c) screening protocols

456 including interviews, questionnaires and minimally invasive physical assessments, when performed
457 for research purposes, that could not be expedited under one of the categories listed above.

458 13. Secondary research uses of identifiable private information or identifiable biospecimens that
459 are not exempt under § __.104(d)(4) because (a) the identifiable private information or identifiable
460 biospecimens are not publicly available; (b) information, which may include information about
461 biospecimens, is recorded by the investigator in such a manner that the identity of human
462 participants can be readily ascertained directly or through identifiers linked to the participants, or
463 the investigator intends to contact the participants or will re-identify participants; (c) research use
464 of identifiable health information not regulated under 45 CFR parts 160 and 164, subparts A and E.

465 14. Research involving the use of identifiable private information or identifiable biospecimens for
466 secondary research use that is not exempt under § __.104(d)(8) because the investigator includes
467 returning individual research results to participants as part of the study plan.

468 Continuing Review of Previously Approved Research

469 15. Research previously approved by the convened IRB and not otherwise eligible for expedited
470 review under categories (1) through (13) above, where one of the following conditions apply:
471 the research remains active only for long-term follow-up of participants;5 or
472 no participants have been enrolled at sites under the purview of the reviewing IRB and no
473 additional risks have been identified;

474

475 Procedure for Expedited Review

476 Under an expedited review procedure, the review may be carried out by the IRB chairperson or by one
477 or more experienced reviewers designated by the chairperson from among members of the IRB. In
478 general, two reviewers conduct expedited reviews. The names of the reviewers are included in IRB
479 documentation.

480 Unless an IRB determines otherwise, continuing review of research is not required for research eligible
481 for and approved by expedited review in accordance with § __.109(f)(1)(i).

482 Expedited Review of Minor Changes in Previously Approved Research

483 Investigators must request in writing any proposed changes in IRB-approved research, including
484 proposed changes in informed consent process, documents, or data collection methods. No changes
485 may be initiated without prior approval of the IRB, except where necessary to eliminate apparent
486 immediate hazards to participants.

487 The IRB may use expedited procedures to review a proposed change to previously approved research
488 if it represents a minor change to be implemented during the previously authorized approval period.

489 A minor modification is one which, in the judgment of the IRB reviewer, makes no substantial
490 alteration in the level of risks to participants, the research design or methodology, the number of
491 participants enrolled in the research, the qualifications of the research team, or other factors which
492 would warrant review of the proposed changes by the convened IRB. Any added procedures must
493 involve no more than minimal risk and fall into categories 1-7 of research that would allow review
494 using the expedited procedure.

495 If proposed changes are judged to be more than minor, the proposal will be reviewed by the convened
496 IRB at the next regularly scheduled meeting.

497 **XII. Full Board Review**

498 The Common Rule delineates specific criteria for the approval of research. In addition, the Salish
499 Kootenai College IRB will review research for appropriate conduct and procedures related to any
500 implications for the cultural intellectual property rights of the Confederated Salish & Kootenai Tribes.

501 If a given research protocol does not qualify for expedited or exempt review, as indicated by the
502 criteria above, the protocol will be reviewed by the full IRB with a quorum of members present. The
503 IRB will determine that all of the following requirements are met before approving the proposed
504 research.

505 (1) Level of Risk. The IRB will consider the overall level of risk to participants. The regulations
506 require that the IRB distinguish research that is greater than minimal risk from research that is no
507 greater than minimal risk. Minimal risk is defined as “the probability and magnitude of harm or
508 discomfort anticipated in the research are not greater in and of themselves than those ordinarily
509 encountered in daily life or during the performance of routine physical or psychological
510 examinations or tests.

511 (2) Risks are Minimized. The IRB must determine that risks are minimized by using procedures
512 that are consistent with sound research design and do not expose participants to unnecessary
513 risks.

514 The IRB verifies that the research plan, including research design and methodology, will not place
515 participants at unnecessary risk. Additionally, the IRB will determine whether the researcher and
516 research team has appropriate qualifications to be undertaking the research.

517 (3) Risks Reasonable Relative to Anticipated Benefits. The IRB must determine that the risks of
518 the research are reasonable in relation to the anticipated benefits (if any) to participants, and the
519 importance of the knowledge that may reasonably be expected to result. The IRB will consider
520 only those risks and benefits that result from the research, and should not consider long-range
521 effects (e.g. public policy implications) that arise from the knowledge gained through the research.

522 (4) Equitable Selection of Participants. The IRB should determine that the selection of
523 participants is equitable, in adherence to the concept of “Justice” as set forth in the Belmont
524 Report. To determine equitable selection, the IRB should evaluate the purposes of the research,
525 the research setting, and the inclusion/exclusion criteria.

526 The IRB should be particularly aware of the problems of research involving vulnerable populations,
527 and should be mindful of the importance of including members of minority groups in research,
528 particularly when the research holds out the prospect of benefit to individual participants.

529 (5) Recruitment. The IRB will review any recruitment materials such as flyers, pamphlets, web
530 announcements, or emails. The IRB will review the announcements to ensure that they do not
531 offer benefits beyond those explained in the risk/benefit section. Recruitment materials may
532 not differ materially from the informed consent document. The IRB will determine that
533 payments, incentives, or other benefits offered as a result of participation are reasonable and
534 are not coercive.

535 (6) Review of the Informed Consent Requirements. The IRB must determine that effective and
536 voluntary informed consent is sought from each prospective participant or the participant’s
537 legally authorized representative unless a waiver of consent is approved by the IRB. Reasons
538 for waiving informed consent are delineated below.

539 Informed consent may only be sought under circumstances that provide the participant or
540 legally authorized representative with sufficient opportunity to consider whether or not to

541 participate in the study and that minimize the possibility of coercion or undue influence. The
542 informed consent form must be written in a language understandable by the participant and
543 at a reading level appropriate for the anticipated participants. Informed consent forms should
544 not contain technical jargon that may not be understood by participants.

545 Informed consent information must include the following:

- 546 (a) A short statement that the study involves research and an explanation of the purposes of
547 the research, the expected duration of the subject's participation, a description of the
548 procedures or activities for the participant, an anticipated risks and benefits to
549 participation.
- 550 (b) Reasonably Foreseeable Risks or Discomforts. Informed consent information must
551 describe any reasonably foreseeable risks or discomforts associated with the research.
552 Risks should be listed in descending order of probability.
- 553 (c) Reasonably Expected Benefits to Participants or Others. Informed consent information
554 must describe any benefits to participants or to others that may reasonably be expected
555 from the research. However, care must be taken not to overstate the benefits and create
556 an undue influence on participants. Payment for participation in the research is not
557 considered a benefit of the research.
- 558 (d) Appropriate alternatives if present. Informed consent should disclose any appropriate
559 alternative procedures or courses of treatment. For example, if the research is a particular
560 medical treatment, alternative treatments should be presented.
- 561 (e) Procedures For Confidentiality. Informed consent information must describe the extent to
562 which confidentiality will be maintained or not maintained. Consent information should
563 describe any procedures that the research team will use to protect participants' private
564 records. In some research, loss of privacy may be the greatest risk of participation. If
565 records are subject to inspection or audit by a funding agency or sponsor, a statement
566 should be included indicating that the sponsor may choose to inspect and copy research
567 records that identify individual research participants.
- 568 (f) Compensation or Treatment for Injury. Informed consent information for research
569 involving more than minimal risk must include explanations regarding whether any
570 compensation is available if injury occurs, how participants can receive medical care and
571 treatment for injuries suffered as a result of participation in a research program, a
572 description of any such compensation or treatments or where more information about
573 them is available.
- 574 (g) Contact Information. Informed consent information must include details, including
575 telephone numbers, about who to contact for three specific questions:
- 576 (i.) For answers to questions about the research. The principal investigator and
577 other members of the research team are appropriate contacts for this
578 information.
- 579 (ii.) For answers to questions about participants' rights. The IRB Office telephone
580 number should be provided for this information.
- 581 (iii.) For projects with more than minimal risk, who to contact in the event of a
582 research-related injury. The principal investigator may serve as appropriate
583 contact for this information.

- 584 (h) Voluntary Participation Statement. Informed consent information must contain clear
585 statements of the following:
- 586 (i.) Participation in research is voluntary.
 - 587 (ii.) Refusal to participate not involve a penalty or loss of benefits to which the
588 participant is otherwise entitled.
 - 589 (iii.) The participant may discontinue participation at any time without penalty or
590 loss of benefits to which the participant is otherwise entitled.
- 591 (i) Additional Elements Where Appropriate. If appropriate the following elements should be
592 included in the informed consent:
- 593 (i.) Additional Costs. If the participant must bear any additional costs, e.g.
594 transportation, health costs, time away from work, the informed consent
595 should specify this information.
 - 596 (ii.) Investigator-initiated Termination of Participation. If there are instances or
597 circumstances that would require investigators to terminate the participation
598 of particular participants (e.g. noncompliance with research), the informed
599 consent information should specify those circumstances.
 - 600 (iii.) Significant New Findings. If there is a possibility that during the course of
601 research, significant new knowledge or findings might impact the participants'
602 willingness to continue participation, the informed consent should detail the
603 procedures for contacting participants about this new information and
604 affirming their continued participation.
- 605 (j) In considering the adequacy of informed consent procedures, the IRB may require special
606 monitoring of the consent process by an impartial observer, or include a required “waiting
607 period” within the consent process.
- 608 (k) The IRB may consent to waive informed consent requirements in specific instances as
609 defined in CFR 45.46.102(e.1.). If there is more than minimal risk to the participants and
610 the only linkage between the participant and research data is the informed consent form,
611 the IRB may provide waiver of consent.
- 612 (l) Broad Consent Information. Salish Kootenai College does not provide for broad consent
613 for use of research specimens or data due to the burden of tracking compliance with
614 broad consent regulations.

615 **Data Safety Monitoring Plans and Review of Reports**

616 The SKC IRB may require monitoring in addition to requirements for annual reporting. This may
617 include a requirement for a Data Safety Monitoring Plan to be developed by the researcher and
618 approved by the IRB. If required, the IRB will specify components to be included in the plan, which
619 may include elements to ensure data integrity, additional protections for participant confidentiality or
620 safety, or additional information about roles and responsibilities related to study coordination and
621 data management. Additionally, the SKC IRB may request periodic reports that include information
622 about informed consent procedures, data safety, unanticipated risks, and other such information.

623 **Disposal of Data and Biospecimens**

624 The SKC IRB may require researchers to provide a detailed plan for storage or disposal of data and/or
625 biospecimens collected during the research process. The plan may include disposal of biospecimens

626 or detailed procedures for storage of data or returning the data to an appropriate tribal entity. If
627 required, the IRB will specify components to be included in the plan and may provide assistance in
628 determining appropriate resolution of data storage and return issues.

629 **Outcomes of IRB Review**

630 IRB actions for research reviewed may include the following:

- 631 (1) Approved with no changes. The research may then proceed.
- 632 (2) Approvable with non-substantive changes to be reviewed by the IRB Administrator or Chair.
633 Such changes must be clearly delineated by the IRB or designated reviewer. The research may
634 proceed after the required changes are verified and the protocol is approved.
- 635 (3) Approvable with substantive changes to be reviewed by the designated reviewer or by the
636 convened IRB. The research may proceed only after the convened IRB has reviewed and approved the
637 required changes to the research, unless the IRB determines that the protocol meets established
638 criteria for expedited review.
- 639 (4) Deferred pending receipt of additional substantive information. If the designated reviewer or
640 IRB determines that it lacks sufficient information about the research to proceed with the review, the
641 IRB may defer or table the review until additional specific information is received. The research may
642 not proceed until the IRB has approved the protocol.
- 643 (5) Disapproved. The IRB has determined that the research cannot be conducted at SKC or by
644 faculty, staff, or students of SKC.

645 **Written Notification of IRB Determination**

646 The IRB provides written notification of its determination to investigators. Notification includes:

- 647 (1) The IRB's decision to approve, disapprove, or require modifications of the research.
- 648 (2) Any modifications or clarifications required by the IRB as a condition for approval.
- 649 (3) If the research is disapproved or approved with modifications, adequate information for the
650 investigator to understand the reasons for the IRB's decision.

651 **Review of Approved Research**

652 The Common Rule requires that the IRB conduct a review of approved research not less than once per
653 year. Therefore the IRB approval period for research is 365 days after the date of approval. No
654 research work can continue on the project after the end of the approval period without a continuing
655 review having been completed and new approval granted by the IRB.

656 If the continuing review is not approved by the date specified, the study approval automatically
657 expires and the study is closed. All research must stop, including recruitment, screening, enrollment,
658 consent, interventions, collection of private identifiable information.

659 **Suspension or Termination of IRB Approval of Research**

660 The IRB is authorized to suspend or terminate research in order to protect the rights and welfare of
661 research participants and others. The IRB Chair or a designated IRB member may temporarily suspend
662 research when there is evidence of the presence of additional risk to participants or others.
663 Suspensions may be lifted if an investigation determines that the harm was not associated with the

664 research, or if compliance with the approved protocol is re-established, and is determined to be
665 sufficient to protect the rights and welfare of human participants. In some cases, protection of the
666 rights and welfare of the research participants may require the transfer of the study to a different
667 researcher, or the continuation of the protocol under a stricter monitoring protocol.

668 **SKC Student Class Projects Requiring IRB Review**

669 SKC students who are conducting research as a component of their academic work must follow the
670 IRB procedures for conducting student research. These procedures are contained as a separate
671 document that may be downloaded from the SKC IRB website.

672 IRB review is required for class projects that do not meet the criteria and include the following
673 types of projects: class projects that may be published or presented outside of the college and
674 independent studies such as honors theses, Master's theses, and similar independent research
675 projects. All of these must be reviewed and approved by the IRB before students may begin their
676 research.

677 Responsibilities of Instructors

- 678 • Instructors are responsible for ensuring appropriate design and ethical conduct of class projects
679 involving human participants data or cultural intellectual property of the CSKT.
- 680 • Instructors are responsible for review of each student's project to determine whether the
681 project does or does not meet the above definition of research and therefore needs review by
682 the IRB.
- 683 • Instructors provide for training in ethical conduct of research projects. If the project will require
684 IRB review and involves human participants, each student must complete the Collaborative
685 Institutional Training Initiative (CITI) training and provide a certificate of training along with the
686 submitted IRB materials.
- 687 • Instructors ensure that appropriate site permissions are obtained for all projects that are
688 completed either as class projects or as formal research.
- 689 • Instructors advise students that data from human participants must not contain any personal
690 and identifying information.
- 691 • Instructors closely monitor class projects to ensure that students are following correct
692 procedures and conducting the project as was proposed.
- 693 • Instructors, to the best of their ability, monitor that the student projects are not shared,
694 presented and/or published outside the SKC community, or submitted into SKC's repository
695 without prior approval from the IRB. Should this occur, the instructor is to contact the IRB
696 immediately.

697 Responsibilities of Students

- 698 • Students are responsible for following the guidelines for class projects as outlined in the course
699 syllabus. Students are responsible for completing training in Human Participants Protection if
700 required as part of an IRB review.
- 701 • Students inform participants that their data will be destroyed after the class project is
702 completed (end of the semester).

- 703 • Students must notify their instructor should the class project change in any way from what was
704 originally proposed.
- 705 • Students do not share, present and/or publish any part of the class project outside the SKC
706 community without prior approval from the IRB.

707 **XIX. IRB Procedures for Research Noncompliance and Research Participant Complaints**

708 1. Research Participant Complaints

709 The Salish Kootenai College IRB is committed to the protection of research participants. Research
710 participants are encouraged to express any concerns or complaints regarding the involvement in a
711 research study. Consent documents must include the investigator's contact information for any
712 questions, complaints and/or concerns the participant or legal representative may have about the
713 research or related matters. Consent documents must also include contact information for the IRB
714 office. Contact information for the IRB is made available for the reporting of questions, complaints
715 and/or concerns. Information about how to report complaints or concerns is also provided on the
716 IRB website.

717 The IRB will investigate all complaints or concerns received regarding human subject research
718 conducted under its jurisdiction. All complaints or concerns will be handled in a confidential
719 manner. This includes any reporting of an alleged violation of investigator compliance.

720 Complaints received by an investigator or members of the research team must be reported to the
721 IRB Chair. All complaints, including those directly reported to the IRB, will be documented in IRB
722 minutes. Records of complaints and communication related to complaints will be maintained in the
723 IRB electronic files. The IRB Chair or designee will respond to the complaint or concern in a timely
724 manner. As necessary, complaints may be brought to the full IRB for discussion and
725 recommendation. If the concern or complaint involves possible non-compliance or research
726 misconduct, the complaint will be handled according to IRB procedures related to research
727 noncompliance or misconduct.

728 2. Procedures for Research Noncompliance or Misconduct

729 The Salish Kootenai College Institutional Review Board complies with federal regulations and
730 applicable ordinances of the Confederated Salish & Kootenai Tribes to review of research studies
731 and communicate certain actions to entities that may have an interest in the status of the research
732 being conducted.

733 Examples of violations include but are not limited to:

- 734 • Doing research with human participants or with considerations for the intellectual property
735 rights of the Confederated Salish & Kootenai Tribes without prior approval of the Board;
- 736 • Doing research in a way different from that described in the approved proposal;
- 737 • Failure to follow approved informed consent procedures;
- 738 • Failure to report adverse reactions, injuries, breaches of confidentiality or detrimental effects;
- 739 • Doing research after approval has expired.

740 The IRB will notify institutional officials, funding sources, and regulatory agencies, as appropriate,
741 once the IRB takes any of the following actions:

- 742 • Determines that an event represents an unanticipated problem involving risks to participants
743 or others;
- 744 • Determines that non-compliance was serious or continuing; or
- 745 • Suspends or terminates approval of research.

746 Allegations of research misconduct will be reported by the IRB Chair to the College President.
747 Inquiry, investigation and hearings will be conducted by the full Institutional Review Board as
748 needed to determine the extent of noncompliance or misconduct and the appropriate response.
749 The IRB Chair will attempt to ensure that the inquiry and final determination as well as appropriate
750 notifications are completed within 30 days of the initiating action. The IRB Chair will expedite
751 responses for serious actions.

752 If the IRB determines that serious research misconduct or noncompliance has occurred, the IRB
753 Chair will prepare a letter that contains the following information:

- 754 • The nature of the event (unanticipated problem involving risks to participants or others,
755 serious or continuing non-compliance, suspension or termination of approval of
756 research);
- 757 • Name of the institution conducting the research;
- 758 • Title of the research project and/or grant proposal in which the problem occurred;
- 759 • Name of the principal investigator on the protocol;
- 760 • Number of the research project assigned by the IRB and the number of any applicable federal
761 award(s) (grant, contract, or cooperative agreement);
- 762 • A detailed description of the problem including the findings of the organization and the
763 reasons for the IRB decision;
- 764 • Corrective actions and/or sanctions the institution is taking or plans to take to address the
765 problem (e.g., revise the protocol, suspend subject enrollment, terminate the research,
766 revise the informed consent document, inform enrolled subjects, increase monitoring
767 of subjects, etc.);
- 768 • Plans, if any, to send a follow-up or final report by a specific date or when an investigation has
769 been completed or a corrective action plan has been implemented.